David T. Hung

8.8k citations

24 papers · 7.1k indexed · 3 hit papers · h-index 17

Impact in

Hematology top 0.1%
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
Genetics top 0.5%
- Coagulation, Bradykinin, Polyphosphates, and Angioedema

Papers in

Hematology 10
- Blood Coagulation and Thrombosis Mechanisms 9
- Platelet Disorders and Treatments 4
Biochemistry 3
- Amino Acid Enzymes and Metabolism 3

Co-authors: Shaun R. Coughlin V I Wheaton Thienkhai Vu T K Vu Tomasz M. Beer Celestia S. Higano Howard I. Scher Charles L. Sawyers
Journals: Journal of Clinical Investigation (3 papers)Alzheimer s & Dementia (2 papers)Coronary Artery Disease (2 papers)Journal of Clinical Oncology (2 papers)Science (2 papers)
Partner nations: United States Switzerland Italy

In The Last Decade

David T. Hung

24 papers receiving 6.9k citations

Hit Papers

align trajectories log scale

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study 2010 · 809 citations

Peers

Countries citing papers authored by David T. Hung

Since Specialization

Citations

This map shows the geographic impact of David T. Hung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Hung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Hung more than expected).

Fields of papers citing papers by David T. Hung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Hung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Hung. The network helps show where David T. Hung may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David T. Hung, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David T. Hung Line = papers co-authored together David T. Hung links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR Bioorganic & Medicinal Chemistry Letters ·L.V. NAZAROVA, Xu QuanBao, Patricia P. Scheible, Wilson Andres González Aguilera, Simranjeet Kaur, Tae-Hyoung Sun, Siddhartha Singh, Raja Kamil, Daniel L. Severance, Sebastián Bernales, Sarvajit Chakravarty, David T. Hung, Son M. Pham, Francisco J. Herrera, Roopa Rai	2016	10
2	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study The Lancet ·Howard I. Scher, Tomasz M. Beer, Celestia S. Higano, Aseem Anand, Mary‐Ellen Taplin, Eleni Efstathiou, Dana E. Rathkopf, Julia Shelkey, Evan Y. Yu, Joshi J. Alumkal, David T. Hung, Mohammad Hirmand, Lynn Seely, Michael J. Morris, Daniel C. Danila, John L. Humm, Steven M. Larson, Martin Fleisher, Charles L. Sawyers Hit paper breakdown →	2010	809
3	Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer Science ·Chris Tran, Samedy Ouk, Nicola J. Clegg, Yu Chen, Philip A. Watson, Vivek Arora, John Wongvipat, Peter Smith‐Jones, Dongwon Yoo, Andrew Kwon, Teresa Wasielewska, Derek S. Welsbie, Р. И. Доброжинская, Celestia S. Higano, Tomasz M. Beer, David T. Hung, Howard I. Scher, Michael E. Jung, Charles L. Sawyers Hit paper breakdown →	2009	1689
4	Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC) Journal of Clinical Oncology ·Howard I. Scher, Tomasz M. Beer, Celestia S. Higano, Mary‐Ellen Taplin, GJ Soukup, Aseem Anand, David T. Hung, W H Lee, Martin Fleisher	2009	33
5	S4‐04–05: Dimebon: A phase 3 investigational agent for Alzheimer's disease with a novel mitochondrial mechanism of action Alzheimer s & Dementia ·David T. Hung	2008	4
6	P4‐334: Eighteen‐month data from an open‐label extension of a one‐year controlled trial of dimebon in patients with mild‐to‐moderate Alzheimer's disease Alzheimer s & Dementia ·Jeffrey L. Cummings, Rachelle S. Doody, Gavrilova Si, Mary Sano, Paul Aisen, Lynn Seely, David T. Hung	2008	2
7	Ductal lavage and the clinical management of women at high risk for breast carcinoma Cancer ·Joyce O’Shaughnessy, Britt‐Marie Ljung, William C. Dooley, Jenny C. Chang, Henry M. Kuerer, David T. Hung, Michael D. Grant, Seema A. Khan, Rogsbert F. Phillips, E. Stepanjan, David Euhus, Bonnie L. King, Benjamin O. Anderson, Susan L. Troyan, Julian Kim, Umberto Veronesi, Massimiliano Cazzaniga	2002	32
8	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR The Lancet ·Ella Evron, William C. Dooley, Christopher B. Umbricht, Dorothy L. Rosenthal, Nicoletta Sacchi, Edward Gabrielson, Ch. Bourgarit, David T. Hung, Britt‐Marie Ljung, Nancy E. Davidson, Saraswati Sukumar	2001	270
9	Novel anticoagulants based on inhibition of the factor Vila/tissue factor pathway Coronary Artery Disease ·Kirk W. Johnson, David T. Hung	1998	7
10	Novel anticoagulants based on inhibition of the factor VIIa/tissue factor pathway Coronary Artery Disease ·Kirk W. Johnson, David T. Hung	1998	3
11	"Mirror image" antagonists of thrombin-induced platelet activation based on thrombin receptor structure. Journal of Clinical Investigation ·David T. Hung, T K Vu, V I Wheaton, Israel Charo, Flavio Amara, N L Esmon, Charles T. Esmon, Shaun R. Coughlin	1992	48
12	Expression Cloning and Characterization of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation Seminars in Thrombosis and Hemostasis ·Shaun R. Coughlin, Thienkhai Vu, David T. Hung, V I Wheaton	1992	28
13	Characterization of a functional thrombin receptor. Issues and opportunities. Journal of Clinical Investigation ·Shaun R. Coughlin, T K Vu, David T. Hung, V I Wheaton	1992	227
14	Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. Journal of Clinical Investigation ·David T. Hung, T K Vu, V I Wheaton, Kenji Ishii, Shaun R. Coughlin	1992	164
15	The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. Journal of Biological Chemistry ·David T. Hung, Yung Hou Wong, T K Vu, Shaun R. Coughlin	1992	213
16	Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. The Journal of Cell Biology ·David T. Hung, Thienkhai Vu, Flavio Amara, Shaun R. Coughlin	1992	133
17	Domains specifying thrombin–receptor interaction Nature ·Thienkhai Vu, V I Wheaton, David T. Hung, Israel Charo, Shaun R. Coughlin	1991	473
18	Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation Cell ·Thienkhai Vu, David T. Hung, V I Wheaton, Shaun R. Coughlin Hit paper breakdown →	1991	2531
19	Potentiation of 1,3-Bis(2-chloroethyl)-1-nitrosourea cytotoxicity in 9L rat brain tumor cells by methylglyoxal-bis(guanylhydrazone), an inhibitor of S-adenosyl-l-methionine decarboxylase European Journal of Cancer and Clinical Oncology ·David T. Hung, Stina Oredsson, Anthony E. Pegg, Dennis F. Deen, Laurence J. Marton	1984	9
20	Depletion of Intracellular Polyamines May Alter DNA Conformation in 9L Rat Brain Tumor Cells Science ·David T. Hung, Laurence J. Marton, Dennis F. Deen, Richard H. Shafer	1983	57

About David T. Hung

David T. Hung is a scholar working on Hematology, Biochemistry, Cancer Research, Immunology and Allergy and Genetics, having authored 24 papers that have together received 7.1k indexed citations. Recurring topics across this work include Blood Coagulation and Thrombosis Mechanisms (9 papers), Platelet Disorders and Treatments (4 papers), Polyamine Metabolism and Applications (4 papers), Prostate Cancer Treatment and Research (4 papers), Amino Acid Enzymes and Metabolism (3 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Epigenetics and DNA Methylation (3 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (3 papers). The work is most often cited by research in Hematology (3.4k citations), Genetics (1.5k citations), Cancer Research (1.8k citations), Pulmonary and Respiratory Medicine (2.3k citations) and Internal Medicine (225 citations). David T. Hung has collaborated with scholars based in United States, Switzerland and Italy. Frequent co-authors include Shaun R. Coughlin, V I Wheaton, Thienkhai Vu, T K Vu, Tomasz M. Beer, Celestia S. Higano, Howard I. Scher, Charles L. Sawyers, Israel Charo and Chris Tran. Their work appears in journals such as Journal of Clinical Investigation, Alzheimer s & Dementia, Coronary Artery Disease, Journal of Clinical Oncology and Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact